Journal article
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease
Abstract
BACKGROUND: In placebo-controlled clinical trials for Crohn's disease (CD), some placebo-treated patients demonstrate improvement. However, it is unclear what factors contribute to placebo response and remission.
METHODS: This was a post hoc analysis of 3 placebo-controlled clinical trial programs (GEMINI-2, UNITI-1/2, and CLASSIC-1) of moderate-severe CD evaluating the efficacy of vedolizumab, ustekinumab, and adalimumab. Baseline predictors …
Authors
Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
Journal
Inflammatory Bowel Diseases, Vol. 29, No. 9, pp. 1390–1398
Publisher
Oxford University Press (OUP)
Publication Date
September 1, 2023
DOI
10.1093/ibd/izac231
ISSN
1078-0998